BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SVACS - ECPv6.15.1.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.siliconvalleyacs.org
X-WR-CALDESC:Events for SVACS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250510T103000
DTEND;TZID=America/Los_Angeles:20250510T120000
DTSTAMP:20260424T003531
CREATED:20250508T160957Z
LAST-MODIFIED:20250508T160957Z
UID:21774-1746873000-1746878400@www.siliconvalleyacs.org
SUMMARY:From the Laboratory to the Marketplace: The Development of a New Drug
DESCRIPTION:Natalie McClure\, Senior Regulatory Affairs and Product Development Consultant\nSponsored by California Section ACS\, Women Chemists Committee\n10:30 am-Noon\, Online\, Free\, May 10\, 2025. Registration required by May 8th at Noon\nDownload the flyer for this event\n\nAbstract\nDrug development requires a delicate balance between innovation\, efficacy\, safety\, and regulatory compliance. This talk will explore the multifaceted process of bringing a new drug from the laboratory to the market\, focusing on the critical role of regulatory affairs in ensuring patient safety and product quality. We will examine the key stages of drug development\, including pre-clinical studies\, clinical trials\, and risk-benefit analysis. We will also discuss how to interpret the package insert. We will discuss how drug developers can work with the FDA to bring the new drug to the market. \nSpeaker Bio\nNatalie McClure is a regulatory affairs consultant with extensive experience in drug development\, regulatory affairs and quality assurance. She obtained a BS in Chemistry from the University of Michigan in 1974 followed by a PhD in Organic Chemistry from Stanford University in 1979. She started her career at Syntex Research\, working in the process development laboratories on new synthetic approaches to prostaglandin and large-scale peptide synthesis and then changed career direction to drug regulatory affairs. \nOver the past 40 years\, she has worked at several different companies\, big and small\, as an individual contributor and executive\, and helped get over 6 drugs approved for marketing. She has filed more than 50 INDs (Investigational New Drugs)\, orphan drug applications and conducted many pre-IND meetings with the FDA. Natalie is an instructor at St Mary’s University and the UC Berkeley Extension program offering several courses in drug development and regulatory affairs. Natalie is also very active in the American Chemical Society serving as chair and councilor of the Silicon Valley local section.
URL:https://www.siliconvalleyacs.org/event/from-the-laboratory-to-the-marketplace-the-development-of-a-new-drug/
LOCATION:Virtual
CATEGORIES:Morning Meeting,Webinar
ATTACH;FMTTYPE=image/png:https://www.siliconvalleyacs.org/wp-content/uploads/2021/02/McClure_Natalie.png
END:VEVENT
END:VCALENDAR